Ratings by Raymond James (Reni Benjamin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/11/2025 | UroGen Pharma | URGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/22/2022 | Voyager Therapeutics | VYGR | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 12/23/2020 | Voyager Therapeutics | VYGR | Downgrade | Market Perform (Outperform) |
9.03 (3.10) |
-65.67% | Details | |
| 11/10/2020 | Voyager Therapeutics | VYGR | Downgrade | Outperform (Strong Buy) |
10.98 (9.03) |
-17.76% | Details | |
| 5/10/2019 | Akebia Therapeutics | AKBA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/9/2019 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Outperform (N/A) |
93.90 (58.40) |
-37.81% | Details | |
| 3/18/2019 | BioTime, Inc. | BTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2019 | UroGen Pharma | URGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2019 | Spark Therapeutics | ONCE | Downgrade | Market Perform (Strong Buy) |
51.56 (110.05) |
113.44% | Details | |
| 2/15/2019 | Incyte | INCY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/7/2019 | Incyte | INCY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/6/2019 | MacroGenics | MGNX | Upgrade | Market Perform (Underperform) |
11.11 (4.30) |
-61.3% | Details | |
| 2/5/2019 | Regenxbio Inc. | RGNX | Upgrade | Strong Buy (Outperform) |
44.53 (46.85) |
5.21% | Details | |
| 12/10/2018 | MacroGenics | MGNX | Downgrade | Underperform (Outperform) |
16.60 (11.11) |
-33.07% | Details | |
| 11/15/2018 | Voyager Therapeutics | VYGR | Upgrade | Strong Buy (Outperform) |
11.80 (3.10) |
-73.73% | Details | |
| 11/12/2018 | Keryx Biopharmaceuticals | KERX | Downgrade | Market Perform (Outperform) |
3.03 (3.36) |
10.89% | Details | |
| 11/7/2018 | Spark Therapeutics | ONCE | Upgrade | Strong Buy (Outperform) |
44.02 (51.56) |
17.13% | Details | |
| 11/2/2018 | Adverum Biotechnologies | ADVM | Downgrade | Market Perform (Outperform) |
4.55 (11.06) |
143.08% | Details | |
| 8/14/2018 | Alpine Immune Sciences | ALPN | New Coverage | Outperform (N/A) |
7.02 (64.97) |
825.5% | Details | |
| 8/14/2018 | Akebia Therapeutics | AKBA | New Coverage | Outperform (N/A) |
8.02 (1.26) |
-84.29% | Details |
